These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23409107)

  • 1. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
    Mansure JJ; Nassim R; Chevalier S; Szymanski K; Rocha J; Aldousari S; Kassouf W
    PLoS One; 2013; 8(2):e55997. PubMed ID: 23409107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
    Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
    Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW; Wu WKK; Loong HHF
    Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
    Colquhoun AJ; Mchugh LA; Tulchinsky E; Kriajevska M; Mellon JK
    J Radiat Res; 2007 Sep; 48(5):351-60. PubMed ID: 17609586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
    Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
    Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Feng YH; Tsao CJ; Wu CL; Chang JG; Lu PJ; Yeh KT; Shieh GS; Shiau AL; Lee JC
    Cancer Sci; 2010 Sep; 101(9):2033-8. PubMed ID: 20624167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
    Mehus AA; Bergum N; Knutson P; Shrestha S; Zhou XD; Garrett SH; Sens DA; Sens MA; Somji S
    PLoS One; 2020; 15(8):e0237976. PubMed ID: 32822399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
    FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
    Shrader M; Pino MS; Brown G; Black P; Adam L; Bar-Eli M; Dinney CP; McConkey DJ
    Mol Cancer Ther; 2007 Jan; 6(1):277-85. PubMed ID: 17237287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
    Peng M; Huang Y; Tao T; Peng CY; Su Q; Xu W; Darko KO; Tao X; Yang X
    Sci Rep; 2016 Jun; 6():28611. PubMed ID: 27334428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
    Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.
    Hayakawa H; Ichihara E; Ohashi K; Ninomiya T; Yasugi M; Takata S; Sakai K; Matsumoto K; Takigawa N; Tanimoto M; Kiura K
    Cancer Sci; 2013 Nov; 104(11):1440-6. PubMed ID: 24033722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.